الإحصائيات الأساسية
| LEI | 213800U8JQHIJOS5AS09 |
| CIK | 1719714 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Mereo BioPharma Group plc - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 001-38452 Not Applicable (State or other jurisdiction of incorporati |
|
| August 12, 2025 |
Exhibit 99.1 Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027 London, August 12, 2025 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”) |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38452 MERE |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 001-38452 Not Applicable (State or other jurisdiction of incorporation) |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 001-38452 Not Applicable (State or other jurisdiction of incorporation) |
|
| May 13, 2025 |
Exhibit 99.1 Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 London, May 13, 2025 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceut |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38452 MER |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 001-38452 Not Applicable (State or other jurisdiction of incorporation) |
|
| April 8, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| March 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 001-38452 Not Applicable (State or other jurisdiction of incorporatio |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38452 MEREO BIOPHARMA GROUP PLC |
|
| March 26, 2025 |
Exhibit 10.31 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED DATED 8 November 2024 DEED OF AMENDMENT AND RESTATEMENT relating to an Amended and Restated Subscription Deed between ASTRAZENECA AB and MEREO BIOPHARMA GROUP PLC This deed (the "Deed") is date |
|
| March 26, 2025 |
Exhibit 99.1 Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) Cash of $69.8 million as o |
|
| March 26, 2025 |
Exhibit 10.32 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED DATED 8 November 2024 AMENDMENT AND RESTATEMENT AGREEMENT relating to an Exclusive License and Option Agreement between ASTRAZENECA AB and MEREO BIOPHARMA 4 LIMITED and MEREO BIOPHARMA GROUP PL |
|
| January 23, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Mereo BioPharma Group plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (2) Proposed Maximum Offering Price Per Share (4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, nominal value £0. |
|
| January 23, 2025 |
As filed with the Securities and Exchange Commission on January 23, 2025 As filed with the Securities and Exchange Commission on January 23, 2025 Registration No. |
|
| January 13, 2025 |
Exhibit 99.1 Mereo BioPharma Provides Update on Lead Clinical Programs Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, receives positive EMA opinion on European Orphan Designation Application; European Commission expected to issue final decision i |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 001-38452 Not Applicable (State or other jurisdiction of incorporat |
|
| December 4, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-283439 PROSPECTUS Mereo BioPharma Group plc 26,638,972 Ordinary Shares Offered by the Selling Shareholders in the form of American Depositary Shares This prospectus covers the offer and resale by the selling shareholders identified in this prospectus of up to an aggregate of 26,638,972 of our ordinary shares in the form of Ame |
|
| December 3, 2024 |
Mereo BioPharma Group plc One Cavendish Place, 4th Floor London, W1G 0QF United Kingdom Mereo BioPharma Group plc One Cavendish Place, 4th Floor London, W1G 0QF United Kingdom December 3, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| November 25, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Mereo BioPharma Group plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Ordinary Shares, nominal value £0. |
|
| November 25, 2024 |
As filed with the Securities and Exchange Commission on November 25, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on November 25, 2024 Registration No. |
|
| November 14, 2024 |
SC 13G/A 1 d1152788913g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Mereo Biopharma Group plc (Name of Issuer) Ordinary shares, nominal value £0.003 per share (Title of Class of Securities) 589492107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| November 14, 2024 |
SC 13G/A 1 ea0221047-13ga2soleus3mereo.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* MEREO BIOPHARMA GROUP PLC (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) September 30, 2024 (Date of Event Which Requ |
|
| November 12, 2024 |
SC 13G/A 1 rocksprings-mreo093024a4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* MEREO BIOPHARMA GROUP PLC (Name of Issuer) Ordinary Shares, nominal value £0.003, per ordinary share (Title of Class of Securities) 589492107** (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38452 MEREO BIOPHARMA G |
|
| November 12, 2024 |
Exhibit 99.1 Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 London, November 12, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focu |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 001-38452 Not Applicable (State or other jurisdiction of incorporat |
|
| August 13, 2024 |
Exhibit 99.1 Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in fracture rates Cash of $87.4 million as of June 30, 2024 expected to fund operations into 2027 |
|
| August 13, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 001-38452 Not Applicable (State or other jurisdiction of incorporati |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38452 MEREO BIOPHARMA GROUP |
|
| June 17, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 15)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Brian Kleinhaus 212-418-1888 (Name, Address |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 001-38452 Not Applicable (State or other jurisdiction of incorporation |
|
| June 14, 2024 |
12,531,300 American Depositary Shares Representing 62,656,500 Ordinary Shares $3.99 per ADS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279433 PROSPECTUS SUPPLEMENT (To Prospectus dated May 22, 2024) 12,531,300 American Depositary Shares Representing 62,656,500 Ordinary Shares $3.99 per ADS We are offering 12,531,300 American Depositary Shares (“ADSs”) at an offering price of $3.99. Each ADS represents five ordinary shares of Mereo BioPharma Group plc. par val |
|
| June 14, 2024 |
Exhibit 99.1 Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market London, June 14, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its America |
|
| June 14, 2024 |
Exhibit 1.1 Mereo BioPharma Group plc (a public limited company incorporated under the laws of England and Wales) 12,531,300 American Depositary Shares Representing 62,656,500 Ordinary Shares UNDERWRITING AGREEMENT June 14, 2024 Jefferies LLC Leerink Partners LLC Cantor Fitzgerald & Co. as Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o Leeri |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 001-38452 Not Applicable (State or other jurisdiction of incorporation |
|
| June 12, 2024 |
EX-99.1 Exhibit 99.1 Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) 14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized f |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 001-38452 Not Applicable (State or other jurisdiction of incorporation) |
|
| May 21, 2024 |
Mereo BioPharma Group plc Fourth Floor One Cavendish Place London W1G 0QF United Kingdom Mereo BioPharma Group plc Fourth Floor One Cavendish Place London W1G 0QF United Kingdom May 21, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Mereo BioPharma Group plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Ordinary Shares, nominal value £0. |
|
| May 15, 2024 |
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update London, May 15, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate highlights |
|
| May 15, 2024 |
As filed with the Securities and Exchange Commission on May 15, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 15, 2024 Registration No. |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38452 MEREO BIOPHARMA GROUP |
|
| May 15, 2024 |
Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM May 15, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Mereo BioPharma Group plc, a public limited company incorporated under the laws of England and Wales with registered number 09481161 (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies L |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 001-38452 Not Applicable (State or other jurisdiction of incorporation) |
|
| April 24, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 16, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 14)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Brian Kleinhaus 212-418-1888 (Name, Address |
|
| April 15, 2024 |
EX-10.1 Exhibit 10.1 Rubric Capital Management L.P. 155 East 44th St, Suite 1630 New York, NY 10017 15 April 2024 Re: Waiver of Section 1(f) of the Cooperation Agreement, dated October 28, 2022, between Mereo BioPharma Group plc (the “Company”) and Rubric Capital Management L.P. (“Rubric Capital”) (such agreement, the “Cooperation Agreement”) and Extension of the Termination Date. To whom it may c |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 001-38452 Not Applicable (State or other jurisdiction of incorporatio |
|
| March 27, 2024 |
Exhibit 99.1 Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update — Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively Partnering discussions for alvelestat progressing with plans to initiate Phase 3 with a partner around |
|
| March 27, 2024 |
Mereo BioPharma Group plc Compensation Recovery Policy Exhibit 97.1 Clawback Policy of Mereo BioPharma Group plc (the “Company”) Introduction: The Board of Directors of the Company (the “Board”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has adopted thi |
|
| March 27, 2024 |
License Agreement, dated December 11, 2023, between Mereo BioPharma Group plc and ReproNovo SA. certain identified information CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT because it is both not material and is the type that the registrant treats as private or confidential. |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38452 MEREO BIOPHARMA GROUP PLC |
|
| March 27, 2024 |
EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the ordinary shares, par value £0.003 per share, of Mereo BioPharma Group plc (the “Company,” “we” or “us”) which are represented by American Depositary Shares (“ADSs”) with each ADS representing five of our ordinary shares registered und |
|
| March 27, 2024 |
Exhibit 19.1 MEREO BIOPHARMA GROUP PLC INSIDER TRADING POLICY This Insider Trading Policy (“Policy”) applies to (a) the purchase or sale of securities in Mereo BioPharma Group plc (including its direct and indirect subsidiaries, and affiliated entities, referred to herein as the “Company”); (b) communications to persons or entities outside the Company of material non‑public information about the C |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 001-38452 Not Applicable (State or other jurisdiction of incorporatio |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. |
|
| February 14, 2024 |
SC 13G/A 1 rocksprings-mreo123123a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* MEREO BIOPHARMA GROUP PLC (Name of Issuer) Ordinary Shares, nominal value £0.003, per ordinary share (Title of Class of Securities) 589492107** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MEREO BIOPHARMA GROUP PLC (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 5, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Mereo Biopharma Group Plc. (Name of Issuer) Ordinary Shares, nominal value £0.003 per share (Title of Class of Securities) 589492107** (CUSIP Number) January 24, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rul |
|
| January 23, 2024 |
As filed with the Securities and Exchange Commission on January 23, 2024 S-8 As filed with the Securities and Exchange Commission on January 23, 2024 Registration No. |
|
| January 23, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) MEREO BIOPHARMA GROUP PLC (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount to be Registered(2) Proposed Maximum Offering Price Per Share(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, nominal value £0. |
|
| January 23, 2024 |
EX-4.3 Exhibit 4.3 MEREO BIOPHARMA GROUP PLC DEFERRED COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS 1. Purpose and Effective Date. The purpose of this Plan is to provide the non-employee members of the Board of Directors (the “Board”) of Mereo BioPharma Group plc and it successors (the “Company”) with an opportunity to (i) elect to receive RSUs (as defined below) in lieu of their cash fees and (ii) |
|
| January 8, 2024 |
EX-99.1 Exhibit 99.1 Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q 2024 and 1H 2024, respectively; Additional Phase 2 data expected in 2024 Alignment on design for s |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales 001-38452 Not Applicable (State or other jurisdiction of incorporati |
|
| December 18, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (A |
|
| December 18, 2023 |
8-A12B/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A/A Amendment No. 3 to Form 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales Not Applicable (State or other jurisdiction of incorporat |
|
| December 18, 2023 |
EX-3.1 Exhibit 3.1 Articles of Association of Mereo BioPharma Group plc The Companies Act 2006 Public Company (as adopted by Special Resolution passed on 16 May 2022 and amended by a Special Resolution passed on 18 December 2023) New Articles of Association of Mereo BioPharma Group plc (the “Company”) (as adopted by Special Resolution passed on 16 May 2022 and amended by a Special Resolution passe |
|
| November 29, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (A |
|
| November 20, 2023 |
MREO / Mereo Biopharma Group Plc - ADR / Rubric Capital Management LP - SC 13D/A Activist Investment SC 13D/A 1 tm2331103d1sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 13)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Br |
|
| November 16, 2023 |
EX-99.1 Exhibit 99.1 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to any aspect of the proposals referred to in this notice or as to the action you should take, please take advice from a stockbroker, solicitor, accountant or other independent professional adviser. If you have sold or otherwise transferred all of your ordinary shares in the capital of |
|
| November 16, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (A |
|
| November 15, 2023 |
MREO / Mereo Biopharma Group Plc - ADR / Rubric Capital Management LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 12)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Brian Kleinhaus 212-418-1888 (Name, Address |
|
| November 13, 2023 |
MREO / Mereo Biopharma Group Plc - ADR / Rubric Capital Management LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Brian Kleinhaus 212-418-1888 (Name, Address |
|
| November 8, 2023 |
MREO / Mereo Biopharma Group Plc - ADR / Rubric Capital Management LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Brian Kleinhaus 212-418-1888 (Name, Address |
|
| November 6, 2023 |
MREO / Mereo Biopharma Group Plc - ADR / Rubric Capital Management LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Brian Kleinhaus 212-418-1888 (Name, Address a |
|
| November 2, 2023 |
MREO / Mereo Biopharma Group Plc - ADR / Rubric Capital Management LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Brian Kleinhaus 212-418-1888 (Name, Address a |
|
| October 31, 2023 |
MREO / Mereo Biopharma Group Plc - ADR / Rubric Capital Management LP - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Brian Kleinhaus 212-418-1888 (Name, Address a |
|
| October 23, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Ad |
|
| October 23, 2023 |
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update EX-99.1 Exhibit 99.1 Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update London, October 23, 2023 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information. Recent Program Developments |
|
| October 17, 2023 |
EX-99.1 Exhibit 99.1 Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvement |
|
| October 17, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Ad |
|
| September 20, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom ( |
|
| September 20, 2023 |
Letter of BDO LLP, dated September 20, 2023 EX-16.1 Exhibit 16.1 Tel: +44 (0)118 925 4400 Fax: +44 (0)118 925 4470 www.bdo.co.uk Level 12 Thames Tower Reading Berkshire RG1 1LX September 20, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 16F of Form 20-F in Form 6-K for the event that occurred on September 20, 2023, to be furnished by our former cli |
|
| September 7, 2023 |
EX-99.3 Exhibit 99.3 Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update London, September 7, 2023 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its unaudited interim financial results for the six months ended June 30, 2023 |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addr |
|
| September 7, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included as Exhibit 99.1 to this Report on Form 6-K furnished to the Securities and Exchange Commission, |
|
| September 7, 2023 |
MEREO BIOPHARMA GROUP PLC Condensed Consolidated Statements of Comprehensive Loss Exhibit 99.1 MEREO BIOPHARMA GROUP PLC Condensed Consolidated Statements of Comprehensive Loss (unaudited) Notes Six months ended June 30, 2023 £’000 Six months ended June 30, 2022 £’000 Revenue 3 7,128 — Cost of revenue 3 (2,455 ) 352 Research and development expenses (7,898 ) (13,322 ) Administrative expenses (9,548 ) (8,840 ) Other operating income 3 2,864 — Operating loss (9,909 ) (21,810 ) Fi |
|
| August 10, 2023 |
MREO / Mereo Biopharma Group Plc - ADR / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| July 26, 2023 |
EX-99.A EXHIBIT 99.A EXHIBIT A JOINT FILING AGREEMENT Soleus Private Equity GP III, LLC, a Delaware limited liability company, Soleus Private Equity Fund III, L.P., a Delaware limited partnership, Soleus PE GP III, LLC, a Delaware limited liability company, Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, So |
|
| July 26, 2023 |
SC 13G 1 d542815dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MEREO BIOPHARMA GROUP PLC (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) July 24, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| July 6, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addre |
|
| July 6, 2023 |
EX-99.1 Exhibit 99.1 Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) Pivotal Phase 3 portion of Orbit study now enrolling approximately 195 pediatric and young adult patients Newly initiated Phase 3 Cosmic study now enrolling approximately 65 younger pediatric patients NOVATO, Calif. — July 06, 2023 — Ultr |
|
| June 30, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addre |
|
| June 16, 2023 |
MREO / Mereo Biopharma Group Plc - ADR / Rubric Capital Management LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Brian Kleinhaus 212-418-1888 (Name, Address a |
|
| June 7, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addre |
|
| June 5, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addre |
|
| June 5, 2023 |
EX-99.1 Exhibit 99.1 Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI) Pediatric data show substantial induction of bone production in 1 week and a large increase in bone formation within 3 months of initiating monthly setrusumab treatment Phase 3 sites beginning to screen patients Conference call to d |
|
| May 22, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addres |
|
| May 8, 2023 |
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement EX-99.1 Exhibit 99.1 Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement London, May 8, 2023 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that it received written confirmation from the Nasdaq Stock Market LLC (“Nasdaq”) that it had regained compliance with the min |
|
| May 8, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addres |
|
| May 5, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addres |
|
| May 5, 2023 |
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market EX-99.1 Exhibit 99.1 Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market London, May 5, 2023 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of i |
|
| April 27, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addr |
|
| April 12, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addr |
|
| March 28, 2023 |
EX-13.1 Exhibit 13.1 Certification by the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Mereo BioPharma Group plc (the “Company”) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Denise Scots-Knight, Chief Executive Officer of the C |
|
| March 28, 2023 |
EX-13.2 Exhibit 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Mereo BioPharma Group plc (the “Company”) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christine Fox, Chief Financial Officer of the Company |
|
| March 28, 2023 |
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm EX-15.2 Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement on Form S-8 (No. 333-269388) pertaining to both the Mereo BioPharma Group plc 2019 Equity Incentive Plan, as amended, and the Mereo BioPharma Group plc 2019 Non-Employee Equity Incentive Plan, as amended; (2) |
|
| March 28, 2023 |
EX-4.47 Exhibit 4.47 DATED 2023 MEREO BIOPHARMA GROUP PLC WARRANT INSTRUMENT relating to the issue of warrants entitling the holders to subscribe for Warrant Shares in the capital of MEREO BIOPHARMA GROUP PLC CONTENTS 1 DEFINITIONS AND INTERPRETATION 2 2 CONSTITUTION AND FORM OF WARRANTS 6 3 NUMBER OF WARRANT SHARES 6 4 CERTIFICATES 6 5 TIMING FOR EXERCISE OF SUBSCRIPTION RIGHTS 7 6 EXERCISE OF SU |
|
| March 28, 2023 |
EX-4.17 Exhibit 4.17 PRIVATE AND CONFIDENTIAL [name] [address] [date] Dear [name], Restated Letter of Appointment The Board of Directors (Board) of Mereo BioPharma Group plc (Company) is pleased to confirm your appointment as an independent non-executive [director][chairman] effective as of [date] (Effective Date). Your restated terms pursuant to this letter will become effective on the Effective |
|
| March 28, 2023 |
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EX-12.2 Exhibit 12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Christine Fox, certify that: 1. I have reviewed this annual report on Form 20-F of Mereo BioPharma Group plc (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make t |
|
| March 28, 2023 |
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EX-12.1 Exhibit 12.1 Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Denise Scots-Knight, certify that: 1. I have reviewed this annual report on Form 20-F of Mereo BioPharma Group plc (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to |
|
| March 28, 2023 |
Description of Securities Registered under Section 12 of the Exchange Act. EX-2.2 EXHIBIT 2.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the ordinary shares, par value £0.003 per share, of Mereo BioPharma Group plc (the “Company,” “we” or “us’’) which are represented by American Depositary Shares (“ADSs”) with each ADS representing five of our ordinary shares regist |
|
| March 28, 2023 |
Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights EX-99.1 Exhibit 99.1 Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights — London, March 28, 2023 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the year ended December 31, 2022 and provided an update on recent corporate highlights. “In 2 |
|
| March 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| March 28, 2023 |
EX-4.46 Exhibit 4.46 DEED OF CONSENT AND AMENDMENT TO NOTE INSTRUMENT THIS DEED is dated February 2023 BETWEEN: (1) MEREO BIOPHARMA GROUP PLC, a public limited company incorporated in England and Wales with company number 04206001 whose registered office is at 4th Floor, One Cavendish Place, London, England W1G 0QF (the “Company”); and (2) NOVARTIS PHARMA AG, a company incorporated and registered |
|
| March 28, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addr |
|
| March 28, 2023 |
Consent of BDO LLP, Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm Mereo BioPharma Group plc London, United Kingdom We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-239708 and No. 333-258495) and Form S-8 (No. 333-231636 and No. 333-236498 and No. 333-252147 and No. 333-262151 and No. 333-269388) of Mereo BioPharma Group plc of our report d |
|
| March 21, 2023 |
EX-99.1 Exhibit 99.1 Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1- Antitrypsin Deficiency-Associated Lung Disease Clear path forward with proposed single Phase 3 study evaluating alvelestat at the 240 mg dose level versus placebo at 12-18 months for potential full approval in both the U.S. and EU No additional confirmatory study required Company to host co |
|
| March 21, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addr |
|
| February 14, 2023 |
MREO / Mereo BioPharma Group plc / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 ss1758595sc13ga.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. 2)* Under the Securities Exchange Act of 1934 Mereo BioPharma Group plc (Name of Issuer) Ordinary Share, nominal value £0.003, represented by American Depository Share (Title of Class of Securities) 589492107** (CUSIP Number) December 31, 2022 (Date of Ev |
|
| February 14, 2023 |
EX-99 2 ss1758595ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated December 31, 2022 (the “Schedule 13G”), with respect to the Ordinary Share, par value £0.003 per share, of Mereo BioPharma Group plc is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the |
|
| February 14, 2023 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Mereo BioPharma Group plc (Title of Class of Securities) Ordinary shares, nominal val |
|
| February 14, 2023 |
MREO / Mereo BioPharma Group plc / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SC 13G/A 1 tm234999d3sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 2)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, nominal value £0.003 per share (Title of Class of Securities) 589492107** (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4) * Mereo BioPharma Group plc (Name of Issuer) American Depositary Share, each representing five Ordinary Shares, nominal value £0.003 per share (Title of Class of Securities) 589492107 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing |
|
| February 14, 2023 |
MREO / Mereo BioPharma Group plc / Rock Springs Capital Management LP Passive Investment SC 13G/A 1 rocksprings-mreo123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* MEREO BIOPHARMA GROUP PLC (Name of Issuer) Ordinary Shares, nominal value £0.003, per ordinary share (Title of Class of Securities) 589492107** (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing |
|
| February 14, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| February 13, 2023 |
MREO / Mereo BioPharma Group plc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 24, 2023 |
As filed with the Securities and Exchange Commission on January 24, 2023 S-8 As filed with the Securities and Exchange Commission on January 24, 2023 Registration No. |
|
| January 24, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) MEREO BIOPHARMA GROUP PLC (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount to be Registered(2) Proposed Maximum Offering Price Per Share(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, nominal value £0. |
|
| January 24, 2023 |
EX-4.4 Exhibit 4.4 MEREO BIOPHARMA GROUP PLC 2019 EMPLOYEE EQUITY INCENTIVE PLAN PERFORMANCE BASED RESTRICTED STOCK UNIT AGREEMENT []-[]-202[] Subject to the terms and conditions set forth in this grant letter (the “Grant Letter”) and its Exhibit A below (the Grant Letter and Exhibit A constituting this “Agreement”), Mereo BioPharma Group plc (the “Company”) has granted you (an employee of the Com |
|
| January 24, 2023 |
EX-4.5 Exhibit 4.5 MEREO BIOPHARMA GROUP PLC 2019 EMPLOYEE EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT []-[]-202[] Subject to the terms and conditions set forth in this grant letter (the “Grant Letter”) and its Exhibit A below (the Grant Letter and Exhibit A constituting this “Agreement”), Mereo BioPharma Group plc (the “Company”) has granted you (an employee of the Company) as of |
|
| November 10, 2022 |
6-K 1 d419997d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0 |
|
| November 10, 2022 |
6-K 1 d414639d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0 |
|
| November 2, 2022 |
MEREO BIOPHARMA GROUP PLC Condensed Consolidated Statements of Comprehensive (Loss)/Income Exhibit 99.1 MEREO BIOPHARMA GROUP PLC Condensed Consolidated Statements of Comprehensive (Loss)/Income (unaudited) Notes Six months ended June 30, 2022 £’000 Six months ended June 30, 2021 £’000 Revenue 3 — 36,464 Cost of revenue 3 352 (18,137 ) Research and development expenses (13,322 ) (9,858 ) Administrative expenses (8,840 ) (8,673 ) Operating loss (21,810 ) (204 ) Finance income 4 173 1 Fin |
|
| November 2, 2022 |
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency EX-99.1 Exhibit 99.1 Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency LONDON, Nov. 2, 2022 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that on November 1, 2022, it received a notification letter from the Listing Qualifications De |
|
| November 2, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (A |
|
| November 2, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion of our financial condition and results of operations should be read in conjunction with Mereo’s unaudited condensed consolidated financial statements and related notes included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities and Exchange Commiss |
|
| November 2, 2022 |
The Company’s report on Form 6-K furnished to the SEC on November 2, 2022; UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 20 22 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4 th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Add |
|
| October 28, 2022 |
EX-99.2 Exhibit 99.2 COOPERATION AGREEMENT This cooperation agreement, dated October 28, 2022 (this “Agreement”), is by and between Mereo BioPharma Group plc, a company incorporated under the laws of England and Wales with registered number 09481161 and having its registered office at 4th Floor, One, Cavendish Place, London, England, W1G 0QF (the “Company”) and Rubric Capital Management L.P., a li |
|
| October 28, 2022 |
Exhibit 1: Cooperation Agreement with Joint Press Release attached thereto as Exhibit A Exhibit 1 COOPERATION AGREEMENT This cooperation agreement, dated October 28, 2022 (this ?Agreement?), is by and between Mereo BioPharma Group plc, a company incorporated under the laws of England and Wales with registered number 09481161 and having its registered office at 4th Floor, One, Cavendish Place, London, England, W1G 0QF (the ?Company?) and Rubric Capital Management L. |
|
| October 28, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Ad |
|
| October 28, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Brian Kleinhaus 212-418-1888 (Name, Address a |
|
| October 28, 2022 |
EX-99.1 Exhibit 99.1 Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management Mereo to Appoint Four New Directors to its Board of Directors Rubric has Withdrawn its General Meeting Requisition Notice and Related Proposals; Agrees to Standstill Provision Through Mereo’s 2024 Annual General Meeting of Shareholders LONDON – October 28, 2022 – Mereo BioPharma Group plc (NASDAQ: MRE |
|
| October 21, 2022 |
6-K 1 d372513d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0Q |
|
| October 21, 2022 |
Exhibit 99.2 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to any aspect of the proposals referred to in this document or as to the action you should take, please take advice from a stockbroker, solicitor, accountant or other independent professional adviser. If you have sold or otherwise transferred all of your ordinary shares in the capital of Mereo |
|
| October 21, 2022 |
Exhibit 99.1 Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting Reiterates Quality and Composition of Mereo?s Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo?s Strategy and Maximize Shareholder Value Details Rubric?s Rejection of Reasonable Settlement Proposals and Refusal to Find a Constructive Solution, Escalating its Costly and Distra |
|
| October 18, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Ad |
|
| October 18, 2022 |
EX-99.1 Exhibit 99.1 Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value Targets 40% Reduction in Headcount and Significant Expense Reductions as Company Continues to Guide Lead Programs Through Upcoming Value Creating Milestones Reiterates Commitment to Disciplined Capital Allocation and Management of Mereo’s Promising Pipeline Provides Encouraging Development Updates o |
|
| October 17, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Ad |
|
| October 17, 2022 |
EX-99.1 Exhibit 99.1 Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease Designation Validates Alvelestat’s Potential to Address a Serious Unmet Need Company Plans R&D Update on Alvelestat in AATD-associated Lung Disease on October 31, 2022 LONDON – October 17, 2022 – Mereo BioPharma Group plc (NASDAQ: MR |
|
| October 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant?s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addres |
|
| October 4, 2022 |
EX-99.1 Exhibit 99.1 Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders Rubric has Rejected Mereo’s Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control of Mereo’s Board Mereo Reiterates Support for its Experienced, Highly Qualified Board and Urges Shareholders to Reject Rubric’s Propos |
|
| September 26, 2022 |
EX-99.1 Exhibit 99.1 Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board Rubric Summarily Rejected the Proposal and Refused to Provide a Counteroffer Rubric’s Second General Meeting Requisition Notice Again Fails to Satisfy Basic Requirements of the Companies Act 2006 which Apply to All U.K. Companies and S |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant?s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addr |
|
| September 23, 2022 |
Exhibit 2: Letter from the Reporting Persons to the shareholders of the Issuer Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders Submits Revised Requisition for General Meeting of Shareholders Condemns Company?s Governance and Corrects the Record on Mereo?s Misleading Public Statements NEW YORK, September 14, 2022 ? Rubric Capital Management LP (?Rubric?), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc (NASDAQ: MREO) (?Mereo? or the ?Company?), today issued an open letter to Mereo?s shareholders. |
|
| September 23, 2022 |
Exhibit 1: Letter to the Issuer: Members’ Requisition of a General Meeting The Directors Mereo Biopharma Group PLC (Mereo or the Company) 4th Floor One Cavendish Place London England W1G 0QF Consistent with section 303(1) of the Companies Act 2006, we, the undersigned, require you to convene a general meeting of the Company, no later than 21 days after you receive this requisition, to consider the removal of Dr. |
|
| September 23, 2022 |
MREO / Mereo BioPharma Group plc / Rubric Capital Management LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Brian Kleinhaus 212-418-1888 (Name, Address a |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant?s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addr |
|
| September 12, 2022 |
Exhibit 99.1 Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy Continued clinical bene |
|
| August 31, 2022 |
Exhibit 99.1 Mereo BioPharma Sends Letter to Rubric Capital Management Letter Reiterates Mereo?s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric?s Assumptions Announces Further Extension of Cash Runway into Q2 2025 LONDON ? August 31, 2022 ? Mereo BioPharma Group plc (NASDAQ: MREO), (?Mereo? or the ?Company?), a clinical-stage biopharmaceutical company focused on |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant?s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Address |
|
| August 24, 2022 |
Letter to the Issuer: Members’ Requisition of a General Meeting Exhibit 1 The Directors Mereo Biopharma Group PLC (Company) 4th Floor One, Cavendish Place London England W1G 0QF Consistent with section 303(1) of the Companies Act 2006, we, the undersigned, require you to proceed to convene a general meeting of the Company, not later than 21 days after you receive this requisition, for the purpose of considering the removal of Dr. |
|
| August 24, 2022 |
MREO / Mereo BioPharma Group plc / Rubric Capital Management LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Brian Kleinhaus 212-418-1888 (Name, Address a |
|
| August 22, 2022 |
Exhibit 99.1 Mereo BioPharma Sends Letter to Rubric Capital Management Notifies Rubric of Certain Deficiencies in its Notice Purporting to Call a General Meeting of Shareholders LONDON ? August 22, 2022 ? Mereo BioPharma Group plc (NASDAQ: MREO), (?Mereo? or ?the Company?), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today sent a letter to Rubric Capital Manag |
|
| August 22, 2022 |
6-K 1 d397393d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF |
|
| August 19, 2022 |
Mereo BioPharma Group plc Fourth Floor One Cavendish Place London W1G 0QF United Kingdom Mereo BioPharma Group plc Fourth Floor One Cavendish Place London W1G 0QF United Kingdom August 19, 2022 VIA EDGAR Tracie Mariner Angela Connell Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| July 5, 2022 |
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement London and Mountain View, CA, July 05, 2022 ? Mereo BioPharma Group plc (NASDAQ: MREO), (?Mereo? or ?the Company?), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it has received a written notification (the ?Notification Letter?) from the Listing Qualifi |
|
| July 5, 2022 |
6-K 1 d306253d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, |
|
| June 14, 2022 |
SC 13D/A 1 tm2218391-1sc13da2.htm AMENDMENT NO. 2 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attent |
|
| June 9, 2022 |
Letter from the Reporting Persons to the Issuer dated June 9, 2022. Exhibit 2 June 9, 2022 The Board of Directors Mereo BioPharma Group PLC 1 Cavendish place London, W1G 0QF Attention: Michael Wyzga, Chairman Dear Members of the Board of Directors: I am writing you on behalf of Rubric Capital Management LP (together, ?Rubric?, ?we?, or ?our?), whose managed funds and accounts collectively own approximately 13. |
|
| June 9, 2022 |
MREO / Mereo BioPharma Group plc / Rubric Capital Management LP - SC 13D/A Activist Investment SC 13D/A 1 tm2218051-1sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Bri |
|
| June 2, 2022 |
Exhibit 99.1 Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan ?ACTIVATE includes 2 Complete Responses, 4 Partial Responses and 10 patients with Stable Disease as of April 2022 data cut off- ?Etigilimab safe and well tolerated, no new safety sign |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant?s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Address o |
|
| May 26, 2022 |
MREO / Mereo BioPharma Group plc / Rubric Capital Management LP - SC 13D Activist Investment SC 13D 1 tm2217079-1sc13d.htm SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) Rubric Capital Management LP 155 East 44th St, Suite 1630 New York, NY 10017 Attention: Brian Kle |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant?s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Address of |
|
| May 26, 2022 |
Exhibit 99.1 Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE) 1 Complete Response (CR), 2 Partial Responses (PR) and 9 cases of Stable Diseases (SD) as |
|
| May 26, 2022 |
6-K 1 d364935d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, U |
|
| May 25, 2022 |
6-K 1 d353313d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, U |
|
| May 17, 2022 |
8-A12B/A 1 d341224d8a12ba.htm 8-A12B/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A/A Amendment No. 2 to Form 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 MEREO BIOPHARMA GROUP PLC (Exact name of registrant as specified in its charter) England and Wales Not Applicable (State or ot |
|
| May 17, 2022 |
Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors Exhibit 99.1 Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors London and Redwood City, Calif., May 17, 2022 - Mereo BioPharma Group plc (NASDAQ: MREO) (?Mereo? or the ?Company?), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul Mullick to the Company?s Board of Directors, effective immedia |
|
| May 17, 2022 |
Exhibit 3.1 Articles of Association of Mereo BioPharma Group plc The Companies Act 2006 Public Company (as adopted by Special Resolution passed on 16 May 2022) New Articles of Association of Mereo BioPharma Group plc (the ?Company?) (as adopted by Special Resolution passed on 16 May 2022) Table of Contents INTERPRETATION AND LIMITATION OF LIABILITY 1 1 Preliminary 1 2 Liability of Members 6 DIRECT |
|
| May 17, 2022 |
6-K 1 d362863d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, U |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant?s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Address of |
|
| May 9, 2022 |
Exhibit 99.1 Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from ?ASTRAEUS? Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period Statistically significant reductions i |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant?s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Address of |
|
| May 9, 2022 |
6-K 1 d296275d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, U |
|
| March 31, 2022 |
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement on Form S-8 (No, 333-231636) pertaining to both the Mereo BioPharma Group plc 2019 Equity Incentive Plan and the Mereo BioPharma Group plc 2019 Non-Employee Equity Incentive Plan; and (2) Registration Statement on Fo |
|
| March 31, 2022 |
Employment Agreement, dated September 1, 2019 between Mereo Biopharma Group plc. and John Richard Exhibit 4.26 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (?Agreement?) is entered into as of September 1, 2019 (the ?Effective Date?) by and between Mereo BioPharma Group Plc, a company incorporated in England and Wales (the ?Company?), and John Richard (?Employee?). WHEREAs, the Company and Employee entered into that certain employment agreement dated |
|
| March 31, 2022 |
Exhibit 16.1 31 March 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 16F ?Change In Registrant?s Certifying Accountant? of Form 20-F dated 31 March 2022, of Mereo BioPharma Group plc and are in agreement with the statements contained in the paragraphs 2, 3, 4 and 5 on page 129 therein. We have no basis to agree or disagree wi |
|
| March 31, 2022 |
6-K 1 d325585d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, |
|
| March 31, 2022 |
Exhibit 4.34 THIS AMENDED AND RESTATED CONTRACT OF EMPLOYMENT dated August 2021 is made BETWEEN: (1) MEREO BIOPHARMA GROUP PLC, (a company incorporated in England and Wales and registered under number 9481161, whose registered office is at 1 Cavendish Place, London W1G 0QF (the ?Company?); and (2) CHRISTINE FOX, 25 Redcliffe Square, Flat 2, London, SW10 This Contract sets out the terms and conditi |
|
| March 31, 2022 |
Deferred Compensation Plan for Non-Employee Directors, dated January 31, 2022 Exhibit 4.44 MEREO BIOPHARMA GROUP PLC DEFERRED COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS 1. Purpose and Effective Date. The purpose of this Plan is to provide the non-employee members of the Board of Directors (the ?Board?) of Mereo BioPharma Group plc and it successors (the ?Company?) with an opportunity to (i) elect to receive RSUs (as defined below) in lieu of their cash fees and (ii) upon |
|
| March 31, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| March 31, 2022 |
EX-13.2 Exhibit 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Mereo BioPharma Group plc (the “Company”) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christine Fox, Chief Financial Officer of the Company |
|
| March 31, 2022 |
Employment Agreement, dated December 7, 2020, between Mereo BioPharma Group plc and Suba Krishnan Exhibit 4.38 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), is entered into effective as of December 7, 2020 (the ?Effective Date?), by and between Mereo BioPharma Group plc, a company incorporated in England and Wales (the ?Company?) and Suba Krishnan (?Executive? and, together with the Company, the ?Parties?). WHEREAS, the Company desires to assure itself of the services of Ex |
|
| March 31, 2022 |
Exhibit 13.1 Certification by the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Mereo BioPharma Group plc (the ?Company?) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, Denise Scots-Knight, Chief Executive Officer of the Company, |
|
| March 31, 2022 |
Exhibit 4.37 THIS AMENDED AND RESTATED CONTRACT OF EMPLOYMENT dated August 2021 is made BETWEEN: (1) MEREO BIOPHARMA GROUP PLC, (a company incorporated in England and Wales and registered under number 9481161, whose registered office is at 1 Cavendish Place, London W1G 0QF (the ?Company?); and (2) ALEXANDRA (WILLS) HUGHES-WILSON, rue du Mail, 59, B-1050 Brussels, Belgium This Contract sets out the |
|
| March 31, 2022 |
Exhibit 4.45 CERTAIN IDENTIFIED INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXECUTION VERSION LICENSE AGREEMENT This LICENSE AGREEMENT (the ?Agreement?) is entered into on January 13, 2020 (the ?Effective Date?) between ONCOMED PHARMACEUTICALS, INC. |
|
| March 31, 2022 |
Exhibit 4.40 MEREO BIOPHARMA 5, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made and entered into by and among [name] (?Executive?), Mereo BioPharma 5, Inc. (the ?Company?) and Mereo BioPharma Group plc (?Parent?), effective as of [date] (the ?Effective Date?). Background A. The Board of Directors of Parent (the ?Board?) recogn |
|
| March 31, 2022 |
Exhibit 4.39 THIS AMENDED AND RESTATED CONTRACT OF EMPLOYMENT dated August 2021 is made BETWEEN: (1) MEREO BIOPHARMA GROUP PLC, (a company incorporated in England and Wales and registered under number 9481161, whose registered office is at 1 Cavendish Place, London W1G 0QF (the ?Company?); and (2) JACKIE PARKIN of 8 Northbourne Road, Clapham, London SW4 7DJ This Contract sets out the terms and con |
|
| March 31, 2022 |
Consent of BDO LLP, Independent Registered Public Accounting Firm Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Mereo BioPharma Group plc London, United Kingdom We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-249341 and No. 333-239708 and No. 333-258495) and Form S-8 (No. 333-231636 and No. 333-236498 and No. 333-252147 and No. 333-262151) of Mereo BioPharma Group plc of our report d |
|
| March 31, 2022 |
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Denise Scots-Knight, certify that: 1. I have reviewed this annual report on Form 20-F of Mereo BioPharma Group plc (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| March 31, 2022 |
Exhibit 4.33 THIS AMENDED AND RESTATED CONTRACT OF EMPLOYMENT dated August 2021 is made BETWEEN: (1) MEREO BIOPHARMA GROUP PLC, (a company incorporated in England and Wales and registered under number 9481161, whose registered office is at 1 Cavendish Place, London W1G 0QF (the ?Company?); and (2) DENISE SCOTS-KNIGHT, One Carlos Place, London, W1K 3AJ This Contract sets out the terms and condition |
|
| March 31, 2022 |
Form of Letter of Appointment for members of the board of directors of Mereo BioPharma Group plc. Exhibit 4.17 PRIVATE AND CONFIDENTIAL [name] [address] [date] Dear [name], Restated Letter of Appointment The Board of Directors (Board) of Mereo BioPharma Group plc (Company) is pleased to confirm your appointment as an independent non-executive [director][chairman] effective as of [date] (Effective Date). Your restated terms pursuant to this letter will become effective on the Effective Date. Th |
|
| March 31, 2022 |
Exhibit 4.36 THIS AMENDED AND RESTATED CONTRACT OF EMPLOYMENT dated August 2021 is made BETWEEN: (1) MEREO BIOPHARMA GROUP PLC, (a company incorporated in England and Wales and registered under number 9481161, whose registered office is at 1 Cavendish Place, London W1G 0QF (the ?Company?); and (2) CHARLES SERMON, 13 Campion Road, Putney, London SW15 6NN This Contract sets out the terms and conditi |
|
| March 31, 2022 |
Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights Exhibit 99.1 Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights ? London and Redwood City, Calif., March 31, 2022 - Mereo BioPharma Group plc (NASDAQ: MREO) (?Mereo? or the ?Company?), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced financial results for the year ended December 31, 2021 and provided an update on recent c |
|
| March 31, 2022 |
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Christine Fox, certify that: 1. I have reviewed this annual report on Form 20-F of Mereo BioPharma Group plc (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the state |
|
| March 31, 2022 |
Exhibit 4.35 THIS AMENDED AND RESTATED CONTRACT OF EMPLOYMENT dated August 2021 is made BETWEEN: (1) MEREO BIOPHARMA GROUP PLC, (a company incorporated in England and Wales and registered under number 9481161, whose registered office is at 1 Cavendish Place, London W1G 0QF (the ?Company?); and (2) ALASTAIR MACKINNON, 50 Hillier Road, London SW11 6AU This Contract sets out the terms and conditions |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant?s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Address |
|
| March 14, 2022 |
EX-99.1 2 d315739dex991.htm EX-99.1 Mereo BioPharma Group plc NASDAQ: MREO March 14 2022 Alvelestat (MPH966) R&D Day Exhibit 99.1 Disclaimer This presentation has been prepared by Mereo BioPharma Group plc (the “Company”) solely for your information and for the purpose of providing background information on the Company, its business and the industry in which it operates or any particular aspect th |
|
| March 1, 2022 |
Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors Exhibit 99.1 Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors London and Redwood City, Calif., March 1, 2022 - Mereo BioPharma Group plc (NASDAQ: MREO), ?Mereo? or ?the Company?, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hyland to the Company?s Board of Directors, effective immediately. Ms. Hy |
|
| March 1, 2022 |
6-K 1 d267021d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2022 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, |
|
| February 15, 2022 |
MREO / Mereo BioPharma Group plc / Rock Springs Capital Management LP Passive Investment SC 13G 1 rocksprings-mreo123121.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MEREO BIOPHARMA GROUP PLC (Name of Issuer) Ordinary Shares, nominal value £0.003, per ordinary share (Title of Class of Securities) 589492107** (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this |
|
| February 14, 2022 |
SC 13G/A 1 m020822a.htm SCHEDULE 13G (AMENDMENT NO. 1) 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Mereo BioPharma Group plc (Tit |
|
| February 14, 2022 |
MREO / Mereo BioPharma Group plc / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SC 13G/A 1 tm224436d16sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, nominal value £0.003 per share (Title of Class of Securities) 589492107** (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check |
|
| February 14, 2022 |
MREO / Mereo BioPharma Group plc / Boxer Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Mereo Biopharma Group plc (Name of Issuer) American Depositary Shares, each representing five Ordinary shares (Title of Class of Securities) 589492107 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appr |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 2)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, ?0.003 par value per share (the ?Shares?) (Title of Class of Securities) 589492 |
|
| February 14, 2022 |
MREO / Mereo BioPharma Group plc / Rubric Capital Management LP - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, par value £0.003 per share (Title of Class of Securities) 589492107** (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| February 11, 2022 |
SC 13G/A 1 ea155480-13ga3vivo9mereo.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* ? Mereo BioPharma Group plc (Name of Issuer) American Depositary Share, each representing five Ordinary Shares, nominal value £0.003 per share (Title of Class of Securities) 589492 |
|
| February 11, 2022 |
CUSIP No. 589492107 SCHEDULE 13G Page 9 of 9 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 11, 2022 (the ?Schedule 13G?), with respect to the Ordinary Share, par value ?0.003 per share, of Mereo BioPharma Group plc is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under th |
|
| February 11, 2022 |
MREO / Mereo BioPharma Group plc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d917153413g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mereo Biopharma Group plc (Name of Issuer) Ordinary shares, nominal value £0.003 per share (Title of Class of Securities) 589492107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 11, 2022 |
MREO / Mereo BioPharma Group plc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. |
|
| January 13, 2022 |
As filed with the Securities and Exchange Commission on January 13, 2022 As filed with the Securities and Exchange Commission on January 13, 2022 Registration No. |
|
| December 22, 2021 |
EX-99.1 2 d273348dex991.htm EX-99.1 Exhibit 99.1 UAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease Alvelestat reported safe and well-tolerated in patients with COVID-19 Alvelestat, on top of standard of care resulted in a more rapid time to improvement in WHO Disease Severity score of > |
|
| December 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2021 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant?s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addre |
|
| December 2, 2021 |
MREO / Mereo BioPharma Group plc / Rubric Capital Management LP - SC 13G Passive Investment SC 13G 1 tm2134468d1sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Mereo BioPharma Group plc (Name of Issuer) Ordinary Shares, par value £0.003 per share (Title of Class of Securities) 589492107** (CUSIP Number) September 30, 2021 (Date of event which requires filing of this statement) Check the ap |
|
| November 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant?s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addre |
|
| November 30, 2021 |
Exhibit 99.1 Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors One complete response, one partial response and four cases of stable disease observed among 15 patients in the efficacy analysis set Etigilimab was well tolerated with a favorable safety profile Conference call today at 8:30am E |
|
| November 4, 2021 |
6-K 1 d255660d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0 |
|
| November 2, 2021 |
Exhibit 99.1 MEREO BIOPHARMA GROUP PLC Condensed Consolidated Statement of Comprehensive Income (unaudited) Notes Six months ended June 30, 2021 ??000 Six months ended June 30, 2020 ??000 Revenue 3 36,464 ? Cost of revenue (18,137 ) ? Research and development expenses (9,858 ) (8,479 ) Administrative expenses (8,673 ) (8,212 ) Operating loss (204 ) (16,691 ) Finance income 1 39 Finance costs 4 (1, |
|
| November 2, 2021 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.2 3 d207254dex992.htm EX-99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion of our financial condition and results of operations should be read in conjunction with Mereo’s unaudited condensed consolidated financial statements and related notes included as Exhibit 99.1 to this Report on Form 6-K submitted to the Sec |
|
| November 2, 2021 |
The Company’s report on Form 6-K furnished to the SEC on November 2, 2021; UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4 th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addr |
|
| October 26, 2021 |
EX-99.1 2 d227135dex991.htm EX-99.1 Exhibit 99.1 Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency London and Redwood City, Calif., October 26, 2021 - Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or the “Company”, a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that the U.S. |
|
| October 26, 2021 |
6-K 1 d247714d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2021 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0Q |
|
| October 26, 2021 |
6-K 1 d227135d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2021 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G 0Q |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2021 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant?s name into English) 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom (Addres |
|
| October 1, 2021 |
Exhibit 99.1 Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting Previously reported data demonstrated dose-dependent, statistically significant bone-building effect at multiple anatomical sites in adult patients with OI that was consisten |
|
| September 29, 2021 |
Mereo BioPharma Group plc Fourth Floor One Cavendish Place London W1G 0QF United Kingdom Mereo BioPharma Group plc Fourth Floor One Cavendish Place London W1G 0QF United Kingdom September 29, 2021 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 27, 2021 |
As filed with the Securities and Exchange Commission on September 27, 2021 Table of Contents As filed with the Securities and Exchange Commission on September 27, 2021 Registration No. |
|
| September 20, 2021 |
6-K 1 d212141d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2021 Commission File Number: 001-38452 MEREO BIOPHARMA GROUP PLC (Translation of registrant’s name into English) 4th Floor, One Cavendish Place, London, W1G |
|
| September 20, 2021 |
Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors Exhibit 99.1 Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors LONDON and REDWOOD CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) - Mereo BioPharma Group plc (NASDAQ: MREO), ?Mereo? or ?the Company?, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Pierre Jacquet, M.D., Ph.D to the Company?s |
|
| September 7, 2021 |
As filed with the Securities and Exchange Commission on September 7, 2021 Table of Contents As filed with the Securities and Exchange Commission on September 7, 2021 Registration No. |
|
| September 7, 2021 |
CORRESP 1 filename1.htm Mayer Brown LLP 1221 Avenue of the Americas New York, NY 10020-1001 United States of America T: +1 212 506 2500 F: +1 212 262 1910 mayerbrown.com David S. Bakst Partner T: +1 212 506 2551 F: +1 212 849 5551 [email protected] September 7, 2021 VIA EDGAR AND ELECTRONIC MAIL Deanna Virginio Joseph McCann United States Securities and Exchange Commission Division of Corporat |
|
| August 13, 2021 |
As filed with the Securities and Exchange Commission on August 13, 2021 Registration No. |
